Invesque Competitors

Extendicare (TSE:EXE) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Extendicare and Invesque's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Extendicare and Invesque, as reported by MarketBeat.com.

Extendicare presently has a consensus price target of C$6.63, indicating a potential downside of 15.39%. Invesque has a consensus price target of C$2.50, indicating a potential downside of 36.06%. Given Extendicare's stronger consensus rating and higher probable upside, analysts clearly believe Extendicare is more favorable than Invesque.

Valuation and Earnings

This table compares Extendicare and Invesque's gross revenue, earnings per share and valuation.

Extendicare has higher revenue and earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Extendicare, indicating that it is currently the more affordable of the two stocks.

Summary

Extendicare beats Invesque on 7 of the 8 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Knight Therapeutics and Invesque's gross revenue, earnings per share and valuation.

Knight Therapeutics has higher earnings, but lower revenue than Invesque. Invesque is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Knight Therapeutics and Invesque, as reported by MarketBeat.

Knight Therapeutics presently has a consensus target price of C$7.42, suggesting a potential upside of 39.41%. Invesque has a consensus target price of C$2.50, suggesting a potential downside of 36.06%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Invesque.

Profitability

This table compares Knight Therapeutics and Invesque's net margins, return on equity and return on assets.

Summary

Knight Therapeutics beats Invesque on 7 of the 8 factors compared between the two stocks.

Invesque (TSE:IVQ) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and HLS Therapeutics' revenue, earnings per share (EPS) and valuation.

HLS Therapeutics has lower revenue, but higher earnings than Invesque. HLS Therapeutics is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and HLS Therapeutics, as provided by MarketBeat.com.

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. HLS Therapeutics has a consensus price target of C$30.50, suggesting a potential upside of 58.85%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Invesque.

Profitability

This table compares Invesque and HLS Therapeutics' net margins, return on equity and return on assets.

Summary

HLS Therapeutics beats Invesque on 7 of the 9 factors compared between the two stocks.

Invesque (TSE:IVQ) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and Aptose Biosciences' revenue, earnings per share (EPS) and valuation.

Aptose Biosciences has lower revenue, but higher earnings than Invesque. Aptose Biosciences is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Aptose Biosciences, as provided by MarketBeat.com.

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Invesque.

Profitability

This table compares Invesque and Aptose Biosciences' net margins, return on equity and return on assets.

Summary

Aptose Biosciences beats Invesque on 4 of the 6 factors compared between the two stocks.

Invesque (TSE:IVQ) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Invesque and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has lower revenue, but higher earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Burcon NutraScience, as provided by MarketBeat.com.

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Given Burcon NutraScience's stronger consensus rating and higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than Invesque.

Profitability

This table compares Invesque and Burcon NutraScience's net margins, return on equity and return on assets.

Summary

Burcon NutraScience beats Invesque on 7 of the 8 factors compared between the two stocks.

Invesque (TSE:IVQ) and Viemed Healthcare (TSE:VMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares Invesque and Viemed Healthcare's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Invesque and Viemed Healthcare's revenue, earnings per share (EPS) and valuation.

Viemed Healthcare has lower revenue, but higher earnings than Invesque. Invesque is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Invesque and Viemed Healthcare, as provided by MarketBeat.com.

Invesque presently has a consensus price target of C$2.50, suggesting a potential downside of 36.06%. Given Invesque's higher probable upside, equities research analysts clearly believe Invesque is more favorable than Viemed Healthcare.

Summary

Viemed Healthcare beats Invesque on 4 of the 6 factors compared between the two stocks.